Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

ZeTong Hong

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
International Immunopharmacology|April 22, 2025
Long-term outcomes in patients with persistent EBV-DNA positivity after primary Epstein-Barr virus infection and clinical implications of rituximab therapyMin Liu, Yaxian Ma, Zetong Hong, et al.
Clinical and Experimental Medicine|June 25, 2025
Angioimmunoblastic T-cell lymphoma: a concise overview encompassing the pathogenetic, pathological, clinical, therapeutical characteristics, and recent advancesYan Feng, Yaxian Ma, Tongjuan Li, et al.
International Immunopharmacology|April 22, 2025
The lncRNA LINC02446 promotes tumor progression and HLH occurrence by regulating the expression of KLRs and IL-10 in EBV-NK-LPDsYaxian Ma, Yuhan Bao, Jiachen Wang, et al.
Journal of Cellular and Molecular Medicine|October 17, 2025
Daratumumab for CD20<sup>-</sup>CD38<sup>+</sup> Relapsed/Refractory Diffuse Large B-Cell LymphomaZeTong Hong, ZhaoYang Hong, YaXian Ma, et al.
Journal of Blood Medicine|June 9, 2026
ATG Plus Post-Transplantation Cyclophosphamide Improves EBV-DNA Clearance and GVHD in Patients of Adult Chronic Active Epstein-Barr Virus Disease Undergoing Allogeneic HSCTMin Liu, Qiuxia Yu, Yang Cao, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
International Immunopharmacology|April 22, 2025
Long-term outcomes in patients with persistent EBV-DNA positivity after primary Epstein-Barr virus infection and clinical implications of rituximab therapyMin Liu, Yaxian Ma, Zetong Hong, et al.
Clinical and Experimental Medicine|June 25, 2025
Angioimmunoblastic T-cell lymphoma: a concise overview encompassing the pathogenetic, pathological, clinical, therapeutical characteristics, and recent advancesYan Feng, Yaxian Ma, Tongjuan Li, et al.
International Immunopharmacology|April 22, 2025
The lncRNA LINC02446 promotes tumor progression and HLH occurrence by regulating the expression of KLRs and IL-10 in EBV-NK-LPDsYaxian Ma, Yuhan Bao, Jiachen Wang, et al.
Journal of Cellular and Molecular Medicine|October 17, 2025
Daratumumab for CD20<sup>-</sup>CD38<sup>+</sup> Relapsed/Refractory Diffuse Large B-Cell LymphomaZeTong Hong, ZhaoYang Hong, YaXian Ma, et al.
Journal of Blood Medicine|June 9, 2026
ATG Plus Post-Transplantation Cyclophosphamide Improves EBV-DNA Clearance and GVHD in Patients of Adult Chronic Active Epstein-Barr Virus Disease Undergoing Allogeneic HSCTMin Liu, Qiuxia Yu, Yang Cao, et al.
Pageof 1